Skip to main content

Table 1 Clinical characteristics of patients (n = 61)

From: Low cyclosporine concentrations in children and time to acute graft versus host disease

CharacteristicsNo (%) or Mean ± SDaGVHD No (%) or Mean ± SDP
Absence (n = 34)Presence (n = 27)
Age (years)   0.166
  < 1237 (60.7%)18 (52.9%)19 (70.4%) 
  ≥ 1224 (39.3%)16 (47.1%)8 (29.6%) 
Sex   0.980
 Female27 (44.3%)15 (44.1%)12 (44.4%) 
 Male34 (55.7%)19 (55.9%)15 (55.6%) 
Body weight (kg)33.8 ± 20.037.2 ± 9.529.5 ± 20.10.138
Diagnosis   0.219
 Acute lymphoblastic leukemia16 (23.2%)7 (20.6%)9 (33.3%) 
 Acute myeloid leukemia22 (36.1%)14 (41.2%)8 (29.6%) 
 Severe plastic anemia11 (18.0%)4 (11.8%)7 (25.9%) 
 Myelodysplastic syndromes7 (11.5%)6 (17.6%)1 (3.7%) 
 Others5 (8.2%)3 (8.8%)2 (7.4%) 
Donor type   0.331
 Sibling22 (36.1%)15 (44.1%)7 (25.9%) 
 Mismatched unrelated13 (21.3%)6 (17.6%)7 (25.9%) 
 Full matched unrelated26 (42.6%)13 (38.2%)13 (48.1%) 
Conditioning regimen   0.112
 Bu/Cy/ATG/Flua13 (21.3%)4 (11.8%)9 (33.3%) 
 Bu/Cy/ATGa7 (11.5%)6 (17.6%)1 (3.7%) 
 Bu/Cya14 (23.0%)9 (26.5%)5 (18.5%) 
 Cy/TBIa8 (13.1%)6 (17.6%)2 (7.4%) 
 Flu/Cy/ATG/TBI1 (1.6%)0 (0%)1 (3.7%) 
 Flu/Cy/ATG10 (16.4%)4 (11.8%)6 (22.2%) 
 Flu/Cy/TBI7 (11.5%)5 (14.7%)2 (7.4%) 
 Cy/ATG1 (1.6%)0 (0%)1 (3.7%) 
Methotrexate   0.041
 Yes48 (78.7%)30 (88.2%)18 (66.7%) 
 No13 (21.3%)4 (11.8%)9 (33.3%) 
Voriconazole   0.685
 Yes6 (9.8%)4 (11.8%)2 (7.4%) 
 No55 (90.2%)30 (88.2%)25 (92.6%) 
AST/ALT   0.735
  < 20051 (83.6%)29 (85.3%)22 (81.5%) 
  ≥ 20010 (16.4%)5 (14.7%)5 (18.5%) 
Kidney injury (NCI CTCAE)   0.008
 Grade 0–150 (82.0%)32 (94.1%)18 (66.7%) 
 Grade 2–511 (18.0%)2 (5.9%)9 (33.3%) 
Week reached initial target CsA concentration   0.098
 02 (3.3%)2 (5.9%)0 (0.0%) 
 116 (26.2%)10 (29.4%)6 (22.2%) 
 233 (54.1%)20 (58.8%)13 (48.1%) 
 37 (11.5%)1 (2.9%)6 (22.2%) 
 43 (4.9%)1 (2.9%)2 (7.4%) 
Initial target concentration reached before engraftment   0.155
 Yes44 (72.1%)27 (79.4%)17 (63.0%) 
 No17 (27.9%)7 (20.6%)10 (37.0%) 
Low CsA concentrations at lag time before aGVHD occurrence    
Lag days 0–6   < 0.001
 Yes28 (45.9%)8 (23.5%)20 (74.1%) 
 No33 (54.1%)26 (76.5%)7 (25.9%) 
Lag days 7–13   < 0.001
 Yes20 (37.0%)3 (8.8%)17 (85.0%) 
 No34 (63.0%)31 (91.2%)3 (15.0%) 
Lag days 14–20   0.007
 Yes17 (38.6%)9 (26.5%)8 (80.0%) 
 No27 (61.4%)25 (73.5%)2 (20.0%) 
  1. aMyeloablative conditioning regimen
  2. aGVHD acute graft-versus-host disease, Bu busulfan, Cy cyclophosphamide, ATG (rabbit) anti-thymocyteglobulin, Flu fludarabine, TBI total body irradiation, AST aspartate aminotransferase, ALT alanine transferase, NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events, CsA cyclosporine